Author + information
- Received April 22, 2019
- Revision received July 8, 2019
- Accepted August 7, 2019
- Published online January 27, 2020.
- Jonathan N. Menachem, MDa,∗ (, )
- Kelly H. Schlendorf, MDa,
- Jeremy A. Mazurek, MDb,
- David P. Bichell, MDc,
- D. Marshall Brinkley, MDa,
- Benjamin P. Frischhertz, MDa,
- Bret A. Mettler, MDc,
- Ashish S. Shah, MDd,
- Sandip Zalawadiya, MBBSa,
- Wendy Book, MDe and
- JoAnn Lindenfeld, MDa
- aDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
- bDivision of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
- cDivision of Pediatric Cardiac Surgery, Vanderbilt University Medical Center, Nashville, Tennessee
- dDepartment of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, Tennessee
- eCardiovascular Medicine, Emory University School of Medicine, Atlanta, Georgia
- ↵∗Address for correspondence:
Dr. Jonathan N. Menachem, Vanderbilt University Medical Center, 1215 21st Avenue South, Suite 5209, Medical Center East, South Tower, Nashville, Tennessee 37232.
• Heart failure is the leading cause of death for adults with congenital heart disease.
• Management of advanced heart failure is complicated and requires a collaborative effort.
• Appropriately identified patients can successfully undergo heart transplantation or mechanical circulatory support.
• Multicenter studies and continued multidisciplinary education are needed to improve outcomes.
As a result of improvements in care for patients with congenital heart disease (CHD), >90% of children born with CHD are expected to survive to adulthood. For those adults, heart failure (HF) is the leading cause of death. Advances in recognition of, and treatments for, these patients continue to improve. Specifically, adults with CHD are candidates for both heart transplantation and mechanical circulatory support. However, challenges remain that require investigation to improve outcomes.
Drs. Lindenfeld, Menachem, and Zalawadiya have served as consultants for Abbott. Dr. Lindenfeld has served as consultant for AstraZeneca, Abbott, Boehringer Ingelheim, Edwards Lifesciences, Novartis, VWave, Relypsa, Impulse Dynamics, and CVRx; and has received grant funding from AstraZeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Barry Greenberg, MD, served as Guest Editor for this paper.
- Received April 22, 2019.
- Revision received July 8, 2019.
- Accepted August 7, 2019.
- 2020 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.